Studies on the biotransformation of indoramin in the patas monkey.
1. Studies on absorption, excretion and biotransformation of the antihypertensive agent indoramin (3-[2-(4-benzamidopiperidino)ethyl]indole hydrochloride) have been carried out in patas monkeys. 2. Absorption of the drug was extensive, as indicated by less than 8% of the dose appearing in faeces as the unchanged compound. 3. Approx. 35% of an orally administered dose of the 3H-labelled drug was recovered in urine while a similar amount was found in faeces. Urinary excretion of total 3H was mono-exponential with a half-life of 17 h. 4. Biotransformation was extensive, the unchanged drug constituting less than 4.5% of the urinary metabolites. The principal identified metabolites were a sulphate conjugate of 3-[2-(4-benzamidopiperidine)ethyl]indol-6-ol and an acid-labile conjugate of the parent drug. A minor metabolite resulting from N-dealkylation of the drug was identified as 4-benzamidopiperidine. Small amounts of 3-[2-(4-[4-hydroxybenzamido]piperidino)-ethyl]indole were found in a dichloromethane extract of acid-hydrolysed urine. 5. The faeces contained only negligible amounts of conjugated metabolites. The principal components were the indole-6-hydroxylated derivative of the parent drug with smaller amounts of the 5-hydroxylated compound and the unchanged compound.
D000818:Animals; D001711:Biotransformation; D004901:Erythrocebus patas; D005243:Feces / Q000032:analysis; D005260:Female; D006868:Hydrolysis; D007211:Indoles / Q000378:metabolism*; D007217:Indoramin / Q000378:metabolism*; D007408:Intestinal Absorption; D008297:Male; D012737:Sex Factors; D013997:Time Factors
D007211:Indoles; D007217:Indoramin